Daclatasvir plus asunaprevir provided sustained virological response in 182 ( 90 % , 95 % CI 85-94 ) patients in the treatment-naive cohort , 168 ( 82 % , 77-87 ) in the non-responder cohort , and 192 ( 82 % , 77-87 ) in the ineligible , intolerant , or ineligible and intolerant cohort .